Earn CME credit: https://www.naccme.com/program/2018-i7956-1
PARP inhibitors are the most commonly used targeted therapy for patients with recurrent ovarian cancer, and the indications for the use of these drugs have expanded in recent months.
This roundtable discussion between Dr. Robert L. Coleman and pharmacy experts in PARP treatment for ovarian cancer is specifically designed for health-system pharmacists, including specialty pharmacists, clinical pharmacists, oncology pharmacists, and other pharmacists involved in the management of patients with ovarian cancer.
Advertisement
© 2018 Imedex, an HMP Company